Emma Raitoharju1, Niku Oksala, Terho Lehtimäki. 1. Department of Clinical Chemistry, Pirkanmaa Hospital District, Fimlab Laboratories and University of Tampere, School of Medicine, Finland;
Abstract
BACKGROUND: MicroRNAs (miRNA, miR) are noncoding RNAs that regulate gene expression by hindering translation. miRNA expression profiles have been shown to differ in vivo and in vitro in many cellular processes associated with cardiovascular diseases (CVDs). The progression of CVDs has also been shown to alter the blood miRNA profile in humans. CONTENT: We summarize the results of animal and cell experiments concerning the miRNA profile in the atherosclerotic process and the changes which occur in the blood miRNA profile of individuals with CVD. We also survey the relationship of these CVD-related miRNAs and their expression in the human advanced atherosclerotic plaque, thereby providing more insight into miRNA function in human atherosclerotic lesions. The miRNAs miR-126, -134, -145, -146a, -198, -210, -340*, and -92a were found to be expressed differently in the blood of individuals affected and unaffected by CVD. These differences paralleled those seen in tissue comparisons of miRNA expression in advanced atherosclerotic plaques and healthy arteries. Furthermore, several miRNAs associated with atherosclerosis in in vitro studies (such as miR-10a, -126, -145, -146a/b, -185, -210, and -326) were expressed in plaques in a similar pattern as was predicted by the in vitro experiments. The clinical implications of miRNAs in atherosclerosis as biomarkers and as possible drug targets are also reviewed. SUMMARY: miRNA profiles in in vitro and in vivo studies as well as in human peripheral blood are quite representative of the miRNA expression in human atherosclerotic plaques. miRNAs appear promising in terms of future clinical applications.
BACKGROUND: MicroRNAs (miRNA, miR) are noncoding RNAs that regulate gene expression by hindering translation. miRNA expression profiles have been shown to differ in vivo and in vitro in many cellular processes associated with cardiovascular diseases (CVDs). The progression of CVDs has also been shown to alter the blood miRNA profile in humans. CONTENT: We summarize the results of animal and cell experiments concerning the miRNA profile in the atherosclerotic process and the changes which occur in the blood miRNA profile of individuals with CVD. We also survey the relationship of these CVD-related miRNAs and their expression in the human advanced atherosclerotic plaque, thereby providing more insight into miRNA function in humanatherosclerotic lesions. The miRNAs miR-126, -134, -145, -146a, -198, -210, -340*, and -92a were found to be expressed differently in the blood of individuals affected and unaffected by CVD. These differences paralleled those seen in tissue comparisons of miRNA expression in advanced atherosclerotic plaques and healthy arteries. Furthermore, several miRNAs associated with atherosclerosis in in vitro studies (such as miR-10a, -126, -145, -146a/b, -185, -210, and -326) were expressed in plaques in a similar pattern as was predicted by the in vitro experiments. The clinical implications of miRNAs in atherosclerosis as biomarkers and as possible drug targets are also reviewed. SUMMARY: miRNA profiles in in vitro and in vivo studies as well as in human peripheral blood are quite representative of the miRNA expression in humanatherosclerotic plaques. miRNAs appear promising in terms of future clinical applications.
Authors: Moo Yong Park; Sandra M Herrmann; Ahmed Saad; Robert Jay Widmer; Hui Tang; Xiang-Yang Zhu; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Nephrol Dial Transplant Date: 2014-10-31 Impact factor: 5.992
Authors: Agnė Šatrauskienė; Rokas Navickas; Aleksandras Laucevičius; Tomas Krilavičius; Rūta Užupytė; Monika Zdanytė; Ligita Ryliškytė; Agnė Jucevičienė; Paul Holvoet Journal: Int J Environ Res Public Health Date: 2021-02-04 Impact factor: 3.390